Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2137461 | Leukemia Research | 2011 | 6 Pages |
Abstract
This report aims to more accurately define the frequency of the involvement of SRC Family Kinases (SFKs) in imatinib- and dasatinib-resistant CML patients. Clinical samples were analysed during in vivo treatment. We confirmed the high frequency of SFKs involvement in Tyrosine kinase inhibitor-resistant CML (52% of the cases) and even further in progressive disease and blast crises (60% of the cases). The SFKs deregulation is also observed in patients harboring BCR-ABL mutations. In T315I and F317L mutated patients, CML-resistance appears to be promoted by SFKs kinase protein reactivation once the BCR-ABL mutated clone has decreased on Omacetaxine.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Sandrine Hayette, Kaddour Chabane, Mauricette Michallet, Estelle Michallat, Pascale Cony-Makhoul, Stéphanie Salesse, Véronique Maguer-Satta, Jean-Pierre Magaud, Franck E. Nicolini,